Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1621 1622 1624 1625 1699
This examiner grants 81% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18286740 | E3 LIGASE BINDERS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 17760479 | COMPOSITIONS AND METHODS COMPRISING SPLICING-DERIVED ANTIGENS FOR TREATING CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18035176 | METHOD FOR STABILIZING AN ORGANIC MATERIAL USING A STABILIZER MIXTURE | Non-Final OA | BASF SE |
| 18009126 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS V | Non-Final OA | BASF SE |
| 18557648 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASE IN TWO-PHASE SYSTEM | Non-Final OA | DSM IP ASSETS B.V. |
| 18297546 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Genentech, Inc. |
| 18027430 | ANTIBACTERIAL COMPOSITION | Non-Final OA | LG CHEM, LTD. |
| 18091139 | CURABLE RESIN COMPOSITION, CURED PRODUCT, DIFFRACTIVE OPTICAL ELEMENT, AND MULTILAYER DIFFRACTIVE OPTICAL ELEMENT | Final Rejection | FUJIFILM Corporation |
| 18035922 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | Non-Final OA | Massachusetts Institute of Technology |
| 18241186 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18044821 | HERBICIDAL COMPOUNDS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 17398478 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | Non-Final OA | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18528215 | RAPAMYCIN ANALOGS AND USES THEREOF | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18092610 | PD-L1/STING CONJUGATES AND METHODS OF USE | Non-Final OA | Incyte Corporation |
| 17629303 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | University of Virginia Patent Foundation |
| 18021334 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | Final Rejection | SHANGHAITECH UNIVERSITY |
| 17451021 | Diaryl-B-Lactam Compound and Preparation Method and Pharmaceutical Use Thereof | Non-Final OA | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences |
| 18430703 | PHARMACEUTICAL KITS AND USES THEREOF FOR TREATING COLORECTAL CANCER | Non-Final OA | Anbogen Therapeutics, Inc. |
| 18286654 | FUNGICIDAL PYRIDONES | Non-Final OA | FMC Corporation |
| 17799774 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | Non-Final OA | Daewoong Pharmaceutical Co., Ltd. |
| 18516585 | Crystalline Polymorphs of a Muscarinic Acetylcholine Receptor Agonist | Non-Final OA | NSC Therapeutics GmbH |
| 18245700 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | Non-Final OA | ESCIENT PHARMACEUTICALS, INC. |
| 18465749 | HIERARCHICAL NANOPOROUS DIAMONDOID SUPERSTRUCTURE | Non-Final OA | King Abdulaziz City for Science and Technology |
| 18553311 | ANTICANCER COMPOSITION INDUCING CELL SENESCENCE AND CELL DEATH | Non-Final OA | OSTEONEUROGEN INC. |
| 18553128 | NEK7 INHIBITORS | Non-Final OA | Halia Therapeutics, Inc. |
| 18278530 | PRODRUGS OF AZO COMPOUNDS AND THEIR SALTS | Non-Final OA | Amneal Pharmaceuticals LLC |
| 18234142 | RELEASABLE CONJUGATES | Non-Final OA | QuiaPEG Pharmaceuticals AB |
| 17913631 | Process for the Production of Ferroportin Inhibitors | Final Rejection | Vifor (International) AG |
| 17615504 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | Non-Final OA | D&D Pharmatech Inc. |
| 18034852 | KRAS G12D INHIBITORS | Final Rejection | Array BioPharma Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy